Abstract:Background: Recent studies have reported that an elevated intracellular glutathione (GSH) level is associated with resistance of non-small cell lung cancer (NSCLC) cell lines to cisplatin (CDDP). It is well-known that GSH is widely used in the clinic as a hepatoprotective agent. However, whether exogenous GSH can affect the sensitivity of NSCLC cells to CDDP remains unclear. The aim of this study is to evaluate the role of exogenous GSH in the resistance of A549 cells to CDDP. Methods: The effect of GSH and CDDP on the proliferation of A549 cells was analyzed by MTT assay. Subsequent experiments were conducted in A549 cells divided into four groups: control group (untreated cells), GSH group (treated with 120 mu g/ml GSH for 48 N. CDDP group (treated with 10 mu G/ml CDDP for 48 h) and CDDP+GSH group (treated with 10 mu g/ml CDDP+120 mu g/ml GSH for 48 M. Apoptosis was detected by flow cytometry. Light microscopy, fluorescence microscopy and electron microscopy were performed to study morphologic and ultrastructural differences among the four groups of cells. Intracellular GSH level and gamma-GCS expression were determined by immunohistochemistry (IHC). Cellular platinum uptake was assessed by inductively coupled plasma mass spectrometry (ICP-MS). Quantitative RT-PCR analysis was performed to measure the expression of caspase3, caspase9, bax, bc1-2 and MDR-1. Western blot analysis was conducted to examine the protein levels of GST-n, MRP-1 and P-gp. Results: Growth inhibition and apoptosis were reduced in A549 cells in the CDDP+GSH group compared to those in the CDDP group 48 h post-treatment. Alterations in cellular morphology and ultrastructure, as well as typical characteristics of apoptosis, were observed. Intracellular GSH and gamma-GCS levels were elevated by exogenous administration of GSH; in contrast, cellular platinum concentration fell rapidly. Relative to the CDDP group, the CDDP+GSH group exhibited 47.92%, 47.82% and 63.75% downregulation in caspase3, caspase9 and bax mRNA expression, respectively, and a 2.17-fold increase in bc1-2 mRNA level. In addition, there were 1.58-fold and 2.67-fold increases in the level of GST-n and MRP-1, respectively; however, the changes in MDR-1 and P-gp levels were not statistically significant. Conclusions: Our data demonstrated that exogenous GSH used as hepatinica in the clinic could induce resistance of A549 cells to CDDP by inhibiting apoptosis, elevating cellular GSH levels, inactivating the mitochondria-mediated signaling pathway, and increasingthe expression of GST-n, y-GCS and MRP1 to increase CDDP efflux.

Reversal Effect of Ginsenoside Rg3 on Cisplatin-Resistant Human Lung Adenocarcinoma Cell Line(a549ddp) and Its Mechanisms

Effect of Lung Resistance-Related Protein on the Resistance to Cisplatin in Human Ovarian Cancer Cell Lines.

Ginsenoside Rb1 for overcoming cisplatin-insensitivity of A549/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1

Ginsenoside Rg3 Attenuates Cisplatin Resistance in Lung Cancer by Downregulating PD-L1 and Resuming Immune.

Reversal Effect of Recombinant Human Endostatin on Cisplatin Resistance Line A549/DDP Human Lung Adenocarcinoma Cells

[Research on the Mechanism of Ginsenoside Rh2 Reversing the Resistance of Lung Adenocarcinoma Cells to Cisplatin].

The Reversing and Molecular Mechanisms of Mir-503 on the Drug-resistance to Cisplatin in A549/DDP Cells

The Reversal Effect of Toremifene on Cisplatin Resistance in Human Lung Adenocarcinoma Cell Lines A549/DDP

[Ginsenoside Rg3 Regulates Cisplatin Resistance in Gastric Cancer by Wnt/β-catenin Signaling Pathway].

In Vitro Study of the Effect of Cyclosporine A, Tetrandrine and Their Combination on the Reversion of Multidrug Resistance in Leukemia Cell Line.

Mir-324-3p Reverses Cisplatin Resistance by Inducing GPX4-mediated Ferroptosis in Lung Adenocarcinoma Cell Line A549

Arctigenin-induced reversal of drug resistance in cisplastin-resistant cell line A549/DDP, and the mechanism involved

Reversal Effect of Aloe Emodin an Cisplatin Resistance Human Lung Adenocarcinoma Cells

Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line

PD‐0332991 Combined with Cisplatin Inhibits Nonsmall Cell Lung Cancer and Reversal of Cisplatin Resistance

MDR1 and MDR3 Genes and Drug Resistance to Cisplatin of Ovarian Cancer Cells

Reversal of Multidrug Resistance by Cisplatin-Loaded Magnetic Fe3O4 Nanoparticles in A549/DDP Lung Cancer Cells in Vitro and in Vivo

Reverse Effect of Genetically Modified Adenovirus H101 on Drug-resistance of A549/DDP Cells to Cisplatin

Exogenous Glutathione Contributes to Cisplatin Resistance in Lung Cancer A549 Cells.

Inhibitor of DNA Binding 3 Reverses Cisplatin Resistance in Human Lung Adenocarcinoma Cells by Regulating the PI3K/Akt Pathway.

Exosome-Reversed Chemoresistance to Cisplatin in Non-Small Lung Cancer Through Transferring miR-613